Zynerba Pharmaceuticals Inc (ZYNE)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Zynerba Pharmaceuticals Inc (ZYNE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013323
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz, Inc., focuses on the development of next-generation synthetic cannabinoid therapeutics. The company’s pipeline product candidates include ZYN002 and ZYN001. Zynerba’s ZYN002 is a synthetic CBD, a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery. Zynerba Pharmaceuticals’s ZYN001, is a pro-drug of THC which enables the transdermal delivery through skin and into the circulatory system via patch. The company’s pipeline candidates target various indications which include refractory epilepsy, osteoarthritis, fragile x syndrome, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals is headquartered in Devon, Pennsylvania, the US.

Zynerba Pharmaceuticals Inc (ZYNE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Zynerba Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Zynerba Pharma Raises USD13 Million in Venture Financing 12
Partnerships 13
Zynerba Pharma Partners with Lohmann Therapie-Systeme 13
Licensing Agreements 14
Zynerba Pharma Enters into Patent Assignment Agreement with Albany College of Pharmacy 14
Equity Offering 15
Zynerba Pharma Plans to Raise up to USD50 Million in Public Offering 15
Zynerba Pharma Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 16
Zynerba Pharma Raises USD48.3 Million in IPO 18
Zynerba Pharmaceuticals Inc – Key Competitors 20
Zynerba Pharmaceuticals Inc – Key Employees 21
Zynerba Pharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Nov 14, 2017: Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights 23
Aug 01, 2017: Zynerba Pharmaceuticals Reports Second Quarter 2017 Financial Results and Operational Highlights 26
May 09, 2017: Zynerba Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Highlights 28
Mar 27, 2017: Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Operational Highlights 30
Nov 14, 2016: Zynerba Pharmaceuticals Reports Third Quarter 2016 Financial Results and Operational Highlights 32
Aug 11, 2016: Zynerba Pharmaceuticals Reports Second Quarter 2016 Financial Results and Organizational Changes 34
May 12, 2016: Zynerba Pharmaceuticals Reports First Quarter 2016 Financial Results and Operational Highlights 36
Mar 14, 2016: Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Operational Highlights 38
Product News 40
12/08/2016: Zynerba Pharmaceuticals to Host Clinical Research Day on December 15, 2016 to Discuss the Role of ZYN002 CBD Gel in Multiple Diseases 40
Product Approvals 41
Feb 25, 2016: Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome 41
Clinical Trials 42
Jan 03, 2017: Zynerba Pharmaceuticals Announces Initiation of the FAB-C Exploratory Phase 2 Clinical Trial of ZYN002 CBD Gel in Patients with Fragile X Syndrome 42
Dec 05, 2016: Zynerba Reports Positive Results for ZYN002 CBD Gel in Phase 1 Studies at 70th Annual Meeting of the American Epilepsy Society 43
Nov 28, 2016: Zynerba Pharmaceuticals to Highlight Data for ZYN002 CBD Gel at the 70th Annual Meeting of the American Epilepsy Society 45
Nov 02, 2016: Zynerba Pharmaceuticals Announces Initiation of STAR 2 Open-Label Extension Clinical Trial for ZYN002 CBD Gel in Adult Refractory Epilepsy Patients 46
Oct 17, 2016: Zynerba Provides Clinical Update for Lead Development Candidate ZYN002 47
Sep 06, 2016: Zynerba Pharmaceuticals Launches Phase 2 Clinical Trial of ZYN002 CBD Gel for Treatment of Osteoarthritis 48
Aug 01, 2016: Zynerba Pharmaceuticals Announces Dosing of First Patients in Phase 2 STAR 1 Clinical Study of ZYN002 CBD Gel in Adult Epilepsy Patients with Refractory Focal Seizures 49
Jun 27, 2016: Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures 50
Apr 12, 2016: Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid 52
Jan 06, 2016: Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Zynerba Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Zynerba Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Zynerba Pharma Raises USD13 Million in Venture Financing 12
Zynerba Pharma Partners with Lohmann Therapie-Systeme 13
Zynerba Pharma Enters into Patent Assignment Agreement with Albany College of Pharmacy 14
Zynerba Pharma Plans to Raise up to USD50 Million in Public Offering 15
Zynerba Pharma Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 16
Zynerba Pharma Raises USD48.3 Million in IPO 18
Zynerba Pharmaceuticals Inc, Key Competitors 20
Zynerba Pharmaceuticals Inc, Key Employees 21
Zynerba Pharmaceuticals Inc, Subsidiaries 22

★海外企業調査レポート[Zynerba Pharmaceuticals Inc (ZYNE)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Barrick Gold Corp:企業の戦略・SWOT・財務情報
    Barrick Gold Corp - Strategy, SWOT and Corporate Finance Report Summary Barrick Gold Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Tesla Energy Operations Inc:企業の戦略的SWOT分析
    Tesla Energy Operations Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • STATS UK Ltd:企業の戦略的SWOT分析
    STATS UK Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Dil Ltd (506414):企業の財務・戦略的SWOT分析
    Summary Dil Ltd (Dil), formerly Duphar-Interfran Ltd, is a developer of medicinal and pharmaceutical products. The company offers products in the areas such as biotechnology, environmental solutions, pharmaceuticals, and vitamins. It also offers services such as health and wellness, entertainment, e …
  • ESSA Pharma Inc (EPI)-製薬・医療分野:企業M&A・提携分析
    Summary Essa Pharma Inc (Essa Pharma) is a clinical-stage pharmaceutical company that carries out the development of small molecule drugs for the treatment castration-resistant prostate cancer (CRPC). The company’s lead product candidate, EPI-506, disrupts androgen receptor (AR) transcriptional acti …
  • Equity Assurance plc:企業の戦略・SWOT・財務情報
    Equity Assurance plc - Strategy, SWOT and Corporate Finance Report Summary Equity Assurance plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Bharti Infratel Ltd:企業の戦略・SWOT・財務分析
    Bharti Infratel Ltd - Strategy, SWOT and Corporate Finance Report Summary Bharti Infratel Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Pioneer Hi-Bred International Inc:企業のM&A・事業提携・投資動向
    Pioneer Hi-Bred International Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pioneer Hi-Bred International Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • KARL STORZ SE & Co KG:企業の戦略的SWOT分析
    KARL STORZ SE & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Collagen Matrix Inc:製品パイプライン分析
    Summary Collagen Matrix Inc (Collagen Matrix) is a medical equipment company that designs, manufactures and markets collagen and mineral-based finished medical devices and bio materials. The company’s products include block bone graft matrix, putty bone graft matrix, bone graft matrix, collagen memb …
  • Kao Corp (4452):企業の財務・戦略的SWOT分析
    Kao Corp (4452) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Bristol-Myers Squibb Co (BMY)-医療機器分野:企業M&A・提携分析
    Summary Bristol-Myers Squibb Company (BMS) is specialty biopharmaceutical company that carries out the discovery, development, licensing, manufacturing, marketing, distribution and sale of medicines to patients with serious diseases. Its primary focus is in cancer, cardiovascular, immunoscience and …
  • LCC International, Inc.:企業の戦略的SWOT分析
    LCC International, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Petoil Petroleum and Petroleum Products International Exploration and Production Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Petoil Petroleum and Petroleum Products International Exploration and Production Inc (Petoil), a subsidiary of Pet Holding Group of Companies is an oil and gas company that offers petroleum exploration and production services. The company’s services include oil field services, mining, petrol …
  • Israel Institute of Technology:製薬・医療:M&Aディール及び事業提携情報
    Summary Israel Institute of Technology (Technion) is a research university that offers science and technology programs. The university offers various undergraduate and graduate programs in biology, biomedical engineering, biotechnology and food engineering, chemical engineering, and medicine and env …
  • Inhibitor Therapeutics Inc (INTI):企業の財務・戦略的SWOT分析
    Inhibitor Therapeutics Inc (INTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Lonrho Ltd:企業のM&A・事業提携・投資動向
    Lonrho Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Lonrho Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Emera Inc (EMA):企業の財務・戦略的SWOT分析
    Emera Inc (EMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Axpo Holding AG:企業の戦略的SWOT分析
    Axpo Holding AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Tulip Star Hotels Limited:企業の戦略・SWOT・財務分析
    Tulip Star Hotels Limited - Strategy, SWOT and Corporate Finance Report Summary Tulip Star Hotels Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆